Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
If overspending hit savings, concentrate on a concrete reset plan: set a short-term goal, cut a few costs, and automate a savings transfer to recover quickly.
24,735 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
SpaceX exploded onto the public markets, and the initial gains grabbed headlines. Two veteran analysts share what the...
A new forecast warns that a 60-day Iran clash could push the federal deficit higher by about $65 billion, on top of t...
NVIDIA stock investors just received a wave of optimism from analysts who see substantial upside as AI adoption accel...
Oil’s 5.7% weekly drop is fueling a rotation into jet, materials, and infrastructure plays as traders reassess fuel c...
A rebound appears to be taking shape in crushed software stocks as earnings from marquee players hint AI cannibalizat...
A mixed-bag forecast brings heat, rain, snow, and Arctic chills across the United States, with notable implications f...
A prominent real estate fund made a bold $5 million move on InvenTrust Properties as the stock trailed the S&P 500. T...
Lam Research surged about 21% from its June trough as markets priced in a slower path for rate hikes. This report wei...
Snowflake reports a sizable rise in remaining performance obligations, underscoring a strengthening data-backlog thes...
Nebius inked a $27 billion AI infrastructure deal with Meta, locking in vast capacity and signaling its edge in the n...
As investors scan early 2026 results, worksport (WKSP) 2026 earnings reveal how a niche hardware maker navigates supp...